乳腺浸润性微乳头状癌的多组学研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.15.001

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (15): 2465-2469.DOI: 10.3760/cma.j.issn.1007-1245.2024.15.001

• 乳腺癌 • 下一篇

乳腺浸润性微乳头状癌的多组学研究进展

闫晨名蔡艺威程立浩范晓瑞贾中明王晓红

滨州医学院附属医院乳腺外科，滨州　256603

收稿日期:2024-02-06 出版日期:2024-08-01 发布日期:2024-09-02
通讯作者: 王晓红，Email：wangxiaohong0607@126.com
基金资助:
国家自然科学基金（81902702）；山东省自然科学基金（ZR2017LH072）；山东省医药卫生科技发展计划（202104010995）

Overview of multi-omics research on invasive micropapillary carcinoma in breast

Yan Chenming, Cai Yiwei, Cheng Lihao, Fan Xiaorui, Jia Zhongming, Wang Xiaohong

Department of Breast Surgery, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2024-02-06 Online:2024-08-01 Published:2024-09-02
Contact: Wang Xiaohong, Email: wangxiaohong0607@126.com
Supported by:
National Natural Science Foundation (81902702); Shandong Natural Science Foundation (ZR2017LH072); Shandong Province Medical and Health Science and Technology Development Plan (202104010995)

摘要/Abstract

摘要：

浸润性微乳头状癌是一种罕见的乳腺浸润性癌，由于其发病率较低，且通常与其他组织学类型（如浸润性导管癌）同时存在，极易漏诊。浸润性微乳头状癌具有较高的侵袭能力，严重影响患者的生活质量。随着多组学技术的进步，浸润性微乳头状癌的分子机制得到了进一步阐明，越来越多的潜在靶点已经被揭示。本文旨在综述浸润性微乳头状癌的多组学研究进展。

关键词:

浸润性微乳头状癌, 多组学, 分子机制, 进展

Abstract:

Invasive micropapillary carcinoma is a rare type of invasive carcinoma of the breast that is highly susceptible to missed diagnosis due to its low incidence and its usual coexistence with other histologic types such as invasive ductal carcinoma. Invasive micropapillary carcinoma has high invasive capacity and severely affects the patients' quality of life. With the advancement of multi-omics technology, the molecular mechanism of invasive micropapillary carcinoma has been further elucidated, and more and more potential targets have been revealed. The aim of this article is to review the progress of multi-omics research on invasive micropapillary carcinoma.

Key words:

Invasive micropapillary carcinoma, , Multi-omics, Molecular mechanism, Progress

闫晨名蔡艺威程立浩范晓瑞贾中明王晓红.

乳腺浸润性微乳头状癌的多组学研究进展 [J]. 国际医药卫生导报, 2024, 30(15): 2465-2469.

Yan Chenming, Cai Yiwei, Cheng Lihao, Fan Xiaorui, Jia Zhongming, Wang Xiaohong.

Overview of multi-omics research on invasive micropapillary carcinoma in breast [J]. International Medicine and Health Guidance News, 2024, 30(15): 2465-2469.

参考文献

[1] Fisher ER, Palekar AS, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4).Ⅵ. Invasive papillary cancer[J]. Am J Clin Pathol, 1980,73(3):313-322. DOI: 10.1093/ajcp/73.3.313.
[2] Yang YL, Liu BB, Zhang X, et al. Invasive micropapillary carcinoma of the breast: an update[J]. Arch Pathol Lab Med, 2016,140(8):799-805. DOI: 10.5858/arpa. 2016-0040-RA.
[3] Sagnak Yilmaz Z, Sarioglu S. Molecular pathology of micropapillary carcinomas: is characteristic morphology related to molecular mechanisms?[J]. Appl Immunohistochem Mol Morphol, 2023,31(5):267-277. DOI: 10.1097/PAI.0000000000001123.
[4] Guo X, Chen L, Lang R, et al. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis[J]. Am J Clin Pathol, 2006,126(5):740-746. DOI: 10.1309/AXYY-4AJT-MNW6-FRMW.
[5] Gruel N, Fuhrmann L, Lodillinsky C, et al. LIN7A is a major determinant of cell-polarity defects in breast carcinomas[J]. Breast Cancer Res, 2016,18(1):23. DOI: 10.1186/s13058-016-0680-x.
[6] Li D, Zhong C, Cheng Y, et al. A competing nomogram to predict survival outcomes in invasive micropapillary breast cancer[J]. J Cancer, 2019,10(27):6801-6812. DOI: 10.7150/jca.27955.
[7] Dieci MV, Smutná V, Scott V, et al. Whole exome sequencing of rare aggressive breast cancer histologies[J]. Breast Cancer Res Treat, 2016,156(1):21-32. DOI: 10.1007/s10549-016-3718-y.
[8] Gruel N, Benhamo V, Bhalshankar J, et al. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast[J]. Breast Cancer Res, 2014,16(3):R46. DOI: 10.1186/bcr3653.
[9] Pareja F, Ferrando L, Lee SSK, et al. The genomic landscape of metastatic histologic special types of invasive breast cancer[J]. NPJ Breast Cancer, 2020,6:53. DOI: 10.1038/s41523-020-00195-4.
[10] Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition[J]. Nature, 2012,486(7403):353-360. DOI: 10.1038/nature11143.
[11] Shi Q, Shao K, Jia H, et al. Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast[J]. Nat Commun, 2022,13(1):111. DOI: 10.1038/s41467-021-27794-4.
[12] Kang N, Zhang Y, Guo S, et al. Genomic and transcriptomic characterization revealed the high sensitivity of targeted therapy and immunotherapy in a subset of endometrial stromal sarcoma[J]. Cancer Res Treat, 2023,55(3):978-991. DOI: 10.4143/crt.2022.1647.
[13] Dorwal P, Abou-Seif C, Ng J, et al. Clear cell sarcoma of the kidney (CCSK) with BCOR-CCNB3 fusion: a rare case report with a brief review of the literature[J]. Pediatr Dev Pathol, 2023,26(2):149-152. DOI: 10.1177/10935266221124377.
[14] Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer[J]. N Engl J Med, 2017,376(22):2109-2121. DOI: 10.1056/NEJMoa1616288.
[15] Denisov EV, Skryabin NA, Vasilyev SA, et al. Relationship between morphological and cytogenetic heterogeneity in invasive micropapillary carcinoma of the breast: a report of one case[J]. J Clin Pathol, 2015,68(9):758-762. DOI: 10.1136/jclinpath-2015-203009.
[16] Li Y, Deng Y, Zhao Y, et al. Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK[J]. Oncogene, 2022,41(41):4658-4672. DOI: 10.1038/s41388-022-02459-8.
[17] Kanomata N, Kurebayashi J, Koike Y, et al. CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature[J]. BMC Cancer, 2019,19(1):76. DOI: 10.1186/s12885-018-5221-9.
[18] Hix LM, Shi YH, Brutkiewicz RR, et al. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis[J]. PLoS One, 2011,6(6):e20702. DOI: 10.1371/journal.pone.0020702.
[19] Zhong J, Wang H, Chen W, et al. Ubiquitylation of MFHAS1 by the ubiquitin ligase praja2 promotes M1 macrophage polarization by activating JNK and p38 pathways[J]. Cell Death Dis, 2017,8(5):e2763. DOI: 10.1038/cddis. 2017.102.
[20] Matsumura Y, Ito Y, Mezawa Y, et al. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial-mesenchymal plasticity[J]. Life Sci Alliance, 2019,2(4):e201900425. DOI: 10.26508/lsa.201900425.
[21] Kramer Z, Kenessey I, Gángó A, et al. Cell polarity and cell adhesion associated gene expression differences between invasive micropapillary and no special type breast carcinomas and their prognostic significance[J]. Sci Rep, 2021,11(1):18484. DOI: 10.1038/s41598-021-97347-8.
[22] Li S, Yang C, Zhai L, et al. Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast[J]. Breast Cancer Res Treat, 2012,136(1):77-87. DOI: 10.1007/s10549-012-2166-6.
[23] Han Y, Li W, Zhi R, et al. Mir-30c regulates metastasis and polarity reversal of tumor cell clusters by targeting mtdh in invasive micropapillary carcinoma of the breast[J], 2020: 1-26.
[24] Lv J, Shi Q, Han Y, et al. Spatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast[J]. Cell Death Dis, 2021,12(12):1095. DOI: 10.1038/s41419-021-04380-6.
[25] Berglund E, Maaskola J, Schultz N, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity[J]. Nat Commun, 2018,9(1):2419. DOI: 10.1038/s41467-018-04724-5.
[26] Menendez JA, Decker JP, Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells[J]. J Cell Biochem, 2005,94(1):1-4. DOI: 10.1002/jcb.20310.
[27] Chen X, Lin Y, Jin X, et al. Integrative proteomic and phosphoproteomic profiling of invasive micropapillary breast carcinoma[J]. J Proteomics, 2022,257:104511. DOI: 10.1016/j.jprot.2022.104511.
[28] Lee JS, Wagner CB, Prelewicz S, et al. Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia[J]. Haematologica, 2023,108(12):3460-3463. DOI: 10.3324/haematol.2022.281967.
[29] Kawano T, Inokuchi J, Eto M, et al. Activators and inhibitors of protein kinase C (PKC): their applications in clinical trials[J]. Pharmaceutics, 2021,13(11):1748. DOI: 10.3390/pharmaceutics13111748.
[30] Ognjenovic NB, Bagheri M, Mohamed GA, et al. Limiting self-renewal of the basal compartment by PKA activation induces differentiation and alters the evolution of mammary tumors[J]. Dev Cell, 2020,55(5):544-557.e6. DOI: 10.1016/j.devcel.2020.10.004.
[31] Sridharan S, Basu A. S6 kinase 2 promotes breast cancer cell survival via Akt[J]. Cancer Res, 2011,71(7):2590-2599. DOI: 10.1158/0008-5472.CAN-10-3253.
[32] Zhi R, Wu K, Zhang J, et al. PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast[J]. Cancer Sci, 2023,114(5):1912-1928. DOI: 10.1111/cas.15724.
[33] Wu K, Li W, Liu H, et al. Metabolome sequencing reveals that protein arginine-n-methyltransferase 1 promotes the progression of invasive micropapillary carcinoma of the breast and predicts a poor prognosis[J]. Am J Pathol, 2023,193(9):1267-1283. DOI: 10.1016/j.ajpath. 2023.05.010.
[34] Aker FV, Ekren E, Dogan M, et al. Clinicopathological features and prognosis of invasive micropapillary carcinoma compared to invasive ductal carcinoma-NOS: worse or better?[J]. J Coll Physicians Surg Pak, 2022,32(9):1196-1201. DOI: 10.29271/jcpsp.2022.09.1196.
[35] Verras GI, Tchabashvili L, Mulita F, et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis[J]. Breast Cancer (Dove Med Press), 2022,14:41-61. DOI: 10.2147/BCTT.S346301.
[36] Eren Kupik G, Altundağ K. The clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas: a single center experience[J]. Balkan Med J, 2022,39(4):275-281. DOI: 10.4274/balkanmedj.galenos.2022.2022-4-7.

乳腺浸润性微乳头状癌的多组学研究进展

Overview of multi-omics research on invasive micropapillary carcinoma in breast

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	曾宪虎李明李子龙项旭田慧李惠珠马龙杰方笑丽陈力唐冉. 中西医关于溃疡性结肠炎的研究进展 [J]. 国际医药卫生导报, 2024, 30(9): 1415-1418.
[2]	高雯雯张翔王红尹雁惠. 小肠细菌过度生长的治疗新进展 [J]. 国际医药卫生导报, 2024, 30(9): 1418-1421.
[3]	孙虓刘成霞王娜郝佳慧储琳琳栗成钰. 探讨胃“炎癌转化”中腐胺与巨噬细胞极化的关系 [J]. 国际医药卫生导报, 2024, 30(9): 1426-1429.
[4]	王文斌郭小花郑兆华郭曼孙力. 帕博利珠单抗联合白蛋白紫杉醇与卡培他滨方案治疗进展期胃癌患者的疗效评估 [J]. 国际医药卫生导报, 2024, 30(9): 1430-1434.
[5]	李纯杜巧婷刘令令. 初产妇产后缺乳中西医治疗研究进展 [J]. 国际医药卫生导报, 2024, 30(9): 1446-1449.
[6]	何祥琴杨芳丁国锋. 中成药相关肝损伤研究进展 [J]. 国际医药卫生导报, 2024, 30(9): 1450-1453.
[7]	杨寿娟张海涛崔明丽王建李洋程艳丽. Wnt信号通路在急性心肌梗死中的研究进展 [J]. 国际医药卫生导报, 2024, 30(8): 1291-1296.
[8]	邹皓珍杨佳席哲帆纪瑞董华. 单细胞RNA测序技术在肾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(8): 1307-1311.
[9]	邵爽郭纪伟孟玮. m⁶A及m⁵C甲基化修饰通过促进细胞增殖与转移影响癌症的发生和发展 [J]. 国际医药卫生导报, 2024, 30(8): 1316-1320.
[10]	赵博李思维邢甜高萍朱宏喆李敏. TRPV1通道在感染性疾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(7): 1057-1062.
[11]	李孟奇李朋杜刚强孙鸿朔张锴. 长骨骨不连的发病率及手术治疗研究进展 [J]. 国际医药卫生导报, 2024, 30(7): 1062-1066.
[12]	丁嘉雯李娜. ESBLs阳性肺炎克雷伯菌的研究进展 [J]. 国际医药卫生导报, 2024, 30(7): 1071-1074.
[13]	陈晓琳, 杨贞. HR-HPV载量与宫颈上皮内病变及宫颈癌相关性的研究进展 [J]. 国际医药卫生导报, 2024, 30(6): 932-935.
[14]	邹皓珍杨佳席哲帆纪瑞董华. 单细胞RNA测序应用于继发性肾病的研究进展 [J]. 国际医药卫生导报, 2024, 30(6): 936-940.
[15]	王宇威李瑞刘超梁葵香. 妊娠相关静脉血栓栓塞症的诊断和防治策略研究进展 [J]. 国际医药卫生导报, 2024, 30(6): 940-945.